MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
Watch Listen Read
Login Nexus Watchlists Settings
  • MARKETSnap
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Investment Compounding Calculator
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
Theme Style
Switch to Dark Mode
ANIK stock logo

ANIK

Anika Therapeutics, Inc.

$9.65
0.6
 (6.63%)
Exchange:   NASDAQ
Market Cap:   139.135M
Shares Outstanding:   3.137M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Devices
   
CEO:  Cheryl Renee Blanchard
Full Time Employees:  288
Address: 
32 Wiggins Avenue
Bedford
MA
1730
US
Website:  https://www.anikatherapeutics.com
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company’s non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Click to read more…

Revenue Segmentation

πŸ”’ You are currently logged out

Login

EPS

πŸ”’ You are currently logged out

Login
View full analyst estimates

Earnings Call

πŸ”’ You are currently logged out

Login
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

(* All numbers are in thousands)

πŸ”’ You are currently logged out

Login

Balance Sheet

(* All numbers are in thousands)

πŸ”’ You are currently logged out

Login

Cash Flow Statement

(* All numbers are in thousands)

πŸ”’ You are currently logged out

Login

Analyst Estimates

(* All numbers are in thousands)

πŸ”’ You are currently logged out

Login

Current Key Metrics

πŸ”’ You are currently logged out

Login

Forward P/E Ratios

πŸ”’ You are currently logged out

Login

SWOT Analysis

πŸ”’ You are currently logged out

Login

At what price to buy it? –
Intrinsic Value Calculator

πŸ”’ Premium Feature

Log in to access the ANIK Intrinsic Value Calculator

πŸ”‘ Log In
πŸ“ Sign Up Free

Get comprehensive stock analysis with premium features

πŸ”’ You are currently logged out

Login
MS_Stock_Embed class not found. Please check plugin configuration.

Relevant news

21-08-2025 14:17
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of InvestorsΒ ofΒ Anika Therapeutics, Inc. –Β ANIK
07-08-2025 07:30
Anika Therapeutics: Undervalued HA Platform With 2027 Catalysts
06-08-2025 10:10
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. – ANIK